Interleukin 3- receptor targeted exosomes inhibit in vitro and in vivo chronic myelogenous Leukemia cell growth

Marta Cristaldi, Stefania Raimondo, Simona Fontana, Girolamo Cirrincione, Francesca Monteleone, Patrizia Diana, Riccardo Alessandro, Daniele Bellavia, Mauro Manno, Stefano Forte, Samuele Raccosta, Giovanna Calabrese, Lorenzo Memeo, Lorenzo Memeo, Gianluca Giavaresi, Daniele Bellavia, Mauro Manno, Samuele Raccosta

Research output: Contribution to journalArticlepeer-review

85 Citations (Scopus)


Despite Imatinib (IM), a selective inhibitor of Bcr-Abl, having led to improved prognosis in Chronic Myeloid Leukemia (CML) patients, acquired resistance and long-term adverse effects is still being encountered. There is, therefore, urgent need to develop alternative strategies to overcome drug resistance. According to the molecules expressed on their surface, exosomes can target specific cells. Exosomes can also be loaded with a variety of molecules, thereby acting as a vehicle for the delivery of therapeutic agents. In this study, we engineered HEK293T cells to express the exosomal protein Lamp2b, fused to a fragment of Interleukin 3 (IL3). The IL3 receptor (IL3-R) is overexpressed in CML blasts compared to normal hematopoietic cells and thus is able to act as a receptor target in a cancer drug delivery system. Here we show that IL3L exosomes, loaded with Imatinib or with BCR-ABL siRNA, are able to target CML cells and inhibit in vitro and in vivo cancer cell growth.
Original languageEnglish
Pages (from-to)1333-1345
Number of pages13
Publication statusPublished - 2017

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Fingerprint Dive into the research topics of 'Interleukin 3- receptor targeted exosomes inhibit in vitro and in vivo chronic myelogenous Leukemia cell growth'. Together they form a unique fingerprint.

Cite this